INDEX

A
Allele-specific primer extension (ASPE) 65–71
Allele-specific probes, see Probes
Allelic discrimination
  TaqMan assay 41–48
  universal bead arrays 59–71
Anchored primers (AP), see Primers
Anticoagulant
citrate (sodium citrate) 11, 165, 274, 276–277, 287
EDTA 4, 80, 94, 147
heparin 165, 213, 300, 316, 325
Arbitrary primers (ARP), see Primers
Arrays, see Microarrays
ASPE, see Allele-specific primer extension (ASPE)

B
BeadChip, see Beads
Beads
  BeadChip array (Illumina) 175–210
  streptavidin-coated 94, 108
universal bead array (Luminex) 59–72
see also Microarrays
Blood cell antigens
  ABO 51–58
  Dombrock (DO) 25–37
  Duffy (FY) 3–13, 25–37
  Kell (KEL) 3–13, 25–37
  Kidd (JK) 3–13, 25–37
  RHc/e 3–13, 21, 25–37
  RHD 3–13, 21, 25–37
  RHe/e 3–13, 21, 25–37
Blood cell lineage 313–322
Blood group, see Blood cell antigens
BODIPY, see Fluorescent dyes

C
Capture oligonucleotides 8, 132
Capture primer 18
Citrate, see Anticoagulant
Complementary RNA (cRNA) synthesis 175–207, 259, 275–281
Cy3, see Fluorescent dyes
Cy5, see Fluorescent dyes

D
DD-PCR, see Polymerase chain reaction (PCR)
Digoxigenin (DIG) 3–13
  anti-DIG antibody 4
  -labeled UTP 4, 7
DIG, see Digoxigenin (DIG)
DNA concentration 8, 92, 100, 102, 332
DNA extraction
  genomic 4, 8, 18, 19, 53, 54, 80, 99, 117
  maternal plasma 145–147
DNA spectrophotometry 8, 334
Dombrock (DO), see Blood cell antigens
Duffy (FY), see Blood cell antigens

E
Endonuclease, see Restriction endonuclease
Erythrocytes 27, 34, 299–301
Ethylenediaminetetraacetate (EDTA) acid, see Anticoagulant
Exonuclease I 18–20, 62, 165–169, 249, 268–269
Expression, see Gene expression

F
Factor II 63
Factor V Leiden 59, 63
Factor XIII 59–60, 63
FAM, see Fluorescent dyes
Fluorescein, see Fluorescent dyes
Fluorescent dyes
  BODIPY 19, 20, 23
  Cy3 119–126, 133–134, 178, 189
  Cy5 119–126, 133–134
  FAM 41–46, 146, 154, 163–164, 168, 315, 327, 328, 332
  fluorescein 28
  Red 640, 28
  TAMRA 19, 20, 23, 146, 328, 332
  VIC 41–46, 146, 154, 163–164, 168
FY, see Blood cell antigens
DNA and RNA Profiling in Human Blood

Index

G
Gene expression .................................. 161, 175, 176, 211, 245, 246, 273, 274, 285, 293, 299, 313
profiling ............................................. 175, 285
Genotyping
blood group ........................................... 3–24
minisequencing .................................. 51–58
single base extension ...................... 15–24
Glycoprotein (GP) .................................. 39, 41
GP, see Glycoprotein (GP)
H
Heparin, see Anticoagulant
HLA, see Human leukocyte antigen (HLA)
HLA-typing ......................................... 89–114
HPA, see Human platelet alloantigens (HPA)
Human leukocyte antigen (HLA) ........... 89–92, 115–119
Human platelet alloantigens (HPA) ...... 39, 40
I
Illumina, see Beads
Interferon-γ (IFN-γ) .............................. 327
Interleukin (IL)
-17A ................................................. 327, 329
-2 .................................................. 327, 329, 333
-6 .................................................. 327, 329
J
JK, see Blood cell antigens
K
Kell (KEL), see Blood cell antigens
Kidd (JK), see Blood cell antigens
L
LDR, see Ligase detection reaction (LDR)
Ligase detection reaction (LDR) ........... 115–127
Luminex, see Beads
M
Megakaryocytes ..................................... 245, 295–298
Melting curve ....................................... 32, 33
Methylenetetrahydrofolate reductase (MTHFR) .... 59
MGB, see Minor groove binder (MGB)
Microarrays
bead-based ........................................ 175–210
GeneChip® ........................................ 179, 180, 245–270
glass slide ......................................... 273–283, 291
miRNA ............................................. 293–298
plate .................................................. 17–22
universal array .................................. 115–127
Microbeads, see Beads
MicroRNA, see RNA
Minisequencing
ABO genotyping .................................. 51–58
blood group genotyping ................... 15–24
see also Pyrosequencing
Minor groove binder (MGB) .................. 42, 45, 46
N
Nuclease
5′-nuclease TaqMan assay ................... 39–49
nuclease-free tube ............................. 185, 230
nuclease-free water ............................ 20, 42, 145, 218, 316
O
Oligo dT 177, 179, 185, 199, 212, 215, 224, 249, 262, 263, 286–290, 304
Oligonucleotide, see Primers
P
PBMC, see Peripheral blood mononuclear cells (PBMC)
PCR, see Polymerase chain reaction (PCR)
Peripheral blood mononuclear cells (PBMC) ... 176, 193, 211–214, 218, 326–337
Plasma ............................................... 143–157
Platelet-rich plasma (PRP) ................. 255, 277, 287
Platelets ......................................... 16, 39, 245, 273–275
leukocyte depletion ......................... 275–277
purification .................................. 246–248, 250–256
Polymerase chain reaction (PCR)
differential display (DD) ................. 211–222
ELISA ................................................. 7–10
multiplex ........................................ 18–20, 59–64, 336
nanoliter .......................................... 161–174
quantitative .................................. 162, 166, 286, 313, 330
real-time ..................................... 25–37, 39–49, 313–322, 323–338
restriction fragment length polymorphism (RFLP) ... 32
sequence-specific primer (SSP) .......... 26
suppression subtractive hybridization (SSH), 223–243
switch mechanism at 5′-end of RNA templates (SMART) ............. 223–243, 285–292
Prenatal genotyping ......................... 143–157
Primers
anchored ............................................ 215
arbitrary .......................................... 221
for blood group genotyping ........... 5, 6, 29–30, 53, 54
for DNA detection in maternal plasma .... 146
for HLA-DQB1 alleles ..................... 105
for HPA genotyping ......................... 45–46
for immun-related mRNAs .............. 327–328
for SAGE/SADE analysis ................. 300
for thrombophilia SNPs ................... 63
for TLR SNPs ................................ 78–80
Probes
- allele-specific for blood groups ........................................ 29–30
- allele-specific for HPA ........................................... 45
- for blood lineage markers ........................................ 315
- for DNA detection in maternal plasma .................. 146
- for immun-related mRNAs ................................. 327, 328

Pyrosequencing
- Toll-like receptor polymorphisms ...................... 73–87

Q
- Quantitative PCR (qPCR), see Polymerase chain reaction (PCR)

R
- Real-time PCR (RT-PCR), see Polymerase chain reaction (PCR)
- Red 640, see Fluorescent dyes
- Red blood cell antigens, see Blood cell antigens
- Red blood cells, see Erythrocytes
- Restriction endonuclease ........................................ 262–263
- Reticulocytes ................................................... 299–311

RNA
- concentration ................................................... 214, 242
- extraction
  - poly A+ RNA (mRNA) .............. 286, 304, 325, 330–331
  - total RNA .......... 176, 182–184, 213–214, 275, 277, 294, 300, 302
- isolation, see extraction
- microRNA .................................................... 293–298
- stabilization .................................................... 175, 178

S
- SADE, see Serial analysis of downsized extracts (SADE)
- SAGE, see Serial analysis of gene expression (SAGE)
- SBE, see Single base extension
- Serial analysis of downsized extracts (SADE) .... 299–311
- Serial analysis of gene expression (SAGE) ......... 245–272, 299–311

Single base extension
- blood group genotyping ................................. 19, 20
  - see also Minisequencing

Single nucleotide polymorphisms (SNPs) ........ 7–8, 16, 39, 51, 59, 75, 89, 115, 129, 161

SMART, see Switch mechanism at the 5′-end of RNA templates (SMART)

SNPs, see Single nucleotide polymorphisms (SNPs)
SSH-PCR, see Polymerase chain reaction (PCR)
Streptavidin
- Alexa477 ................................................. 295, 297
- anti-streptavidin antibody .................................. 181
- Cy3 ........................................... 178, 189, 190
- phycoerythrin ........................................... 61, 62, 181, 207
- sepharose .................................................. 74
  - see also Beads
- Switch mechanism at the 5′-end of RNA templates (SMART) ........ 223–243, 285–292
- SYBR Green® ........................................... 28–33, 161–170, 301, 306, 308

T
- TAMRA, see Fluorescent dyes
- TaqMan
  - allelic discrimination .................................... 42–49
  - end-point .................................................. 161–174
  - real-time ................................................. 145–154, 333
- Thrombophilia .............................................. 59
- Tissue factor pathway inhibitor (TFPI) .............. 59–60, 63
- Tissue growth factor β (TGF-β) ......................... 327, 329
- TLR, see Toll-like receptor (TLR)
- Toll-like receptor (TLR) .................................. 73–87
- Tumor necrose factor α (TNF-α) ....................... 74, 335

U
- UA, see Universal array (UA)

V
- Vacutainer ................................................... 92, 96, 181
- VeraCode, see Beads
- VIC, see Fluorescent dyes
- In vitro transcription (IVT), see Complementary RNA (cRNA) synthesis

W
- Whole blood .......... 8, 61, 92, 96, 117, 145, 166, 175, 176, 193, 287, 302, 323–325

X
- xMAP® .................................................... 59–72
- xTAG™ .................................................... 59–72
Fig. 2.2. Scatter plot diagram of the resultant BODIDY/TAMRA fluorescent output. The horizontal line represents baseline output (<3.54 units) and identifies genotype, QC, or origin failures and empty wells. The two vertical lines identify the genotypic groupings (XX, XY, and YY) and any outliers. Two outliers are identified in Fig. 2.2 and these samples can be selected for repeat analysis.